Discovery and development of the first systemic therapeutics to deliver self-antigens directly to the thymus to harness the body’s natural mechanis...
siRNA candidate EMP-012 in phase I for treatment of COPD EMP-012 targets a distinct inflammatory pathway with enhanced potency and longer dose int...
Reflects Catalent’s unparalleled service and best-in-class capabilities across the pharmaceutical, biotech and consumer health categories Rein...
BD (Becton, Dickinson and Company), a leading medical technology company, will feature the next generation of drug delivery and traceability s...
Company highlights its global expertise and new and expanded capabilities to help biopharma and biotech customers solve global health challenges Thermo ...
SK pharmteco, a global contract development and manufacturing organization (CDMO), announced today a $6.1 million investment in its Rancho Cordova facili...
Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solution...
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, announced that Orion has obtained an exclusive focused commercial...
SALVAT receives FDA approval for Clotic®, an innovative treatment for otomycosis with Orphan Drug Designation Th...
The U.S. Food and Drug Administration (FDA) has approved Gazyva® (obinutuzumab), developed by Genentech, as a treatment for adults with lupus n...
Adcytherix Raises EUR 105M Series A to Accelerate Breakthrough Antibody-Drug Conjugate Pipeline with Strategic Focus on Novel Payloads Financing led b...
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rar...
Resilience is no longer a corporate slogan — it’s the new currency of survival in biopharma. As the sector races between scientific breakthroug...
-Kezar Life Sciences, Inc. a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated di...
© 2025 Biopharma Boardroom. All Rights Reserved.
